While MorphoSys AG CEO Jean-Paul Kress believes the German biotech has a blockbuster on its hands with pelabresib, the firm could still have a tricky time ahead with regulators following the release of mixed data for its closely watched candidate to treat myelofibrosis.
The Munich-based group has presented topline results from the Phase III MANIFEST-2 trial which was evaluating pelabresib, an investigational BET inhibitor that came with MorphoSys’s $1.7bn acquisition of Constellation Pharmaceuticals, Inc. in July 2021, in combination with current standard of care, Incyte's JAK inhibitor Jakavi (ruxolitinib), in patients with myelofibrosis who have not previously been treated with a JAK